RenovoRx, Inc. (RNXT)
1.275
0.00 (0.00%)
USD |
NASDAQ |
Oct 12, 13:54
RenovoRx Net Income (Quarterly) : -2.911M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.911M |
| March 31, 2026 | -3.521M |
| December 31, 2025 | -2.941M |
| September 30, 2025 | -2.912M |
| June 30, 2025 | -2.895M |
| March 31, 2025 | -2.42M |
| December 31, 2024 | -2.878M |
| September 30, 2024 | -2.471M |
| June 30, 2024 | -2.389M |
| March 31, 2024 | -1.076M |
| December 31, 2023 | -3.227M |
| September 30, 2023 | -1.421M |
| June 30, 2023 | -2.327M |
| Date | Value |
|---|---|
| March 31, 2023 | -3.257M |
| December 31, 2022 | -2.156M |
| September 30, 2022 | -2.136M |
| June 30, 2022 | -2.594M |
| March 31, 2022 | -3.003M |
| December 31, 2021 | -2.355M |
| September 30, 2021 | -1.511M |
| June 30, 2021 | -1.31M |
| March 31, 2021 | -1.148M |
| September 30, 2020 | -1.096M |
| June 30, 2020 | -0.773M |
| March 31, 2020 | -1.051M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -19.50M |
| Travere Therapeutics, Inc. | -34.80M |
| REGENXBIO, Inc. | 22.71M |
| Krystal Biotech, Inc. | 54.77M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.909M |
| Total Expenses (Quarterly) | 3.82M |
| EPS Diluted (Quarterly) | -0.0616 |
| Enterprise Value | 48.67M |
| Gross Profit Margin (Quarterly) | 84.27% |
| Profit Margin (Quarterly) | -320.2% |
| Earnings Yield | -24.63% |
| Normalized Earnings Yield | -25.91 |